MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its holdings in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 1.2% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 342,667 shares of the company’s stock after purchasing an additional 4,186 shares during the quarter. JPMorgan Chase & Co. owned 0.44% of MeiraGTx worth $1,429,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Garden State Investment Advisory Services LLC acquired a new stake in MeiraGTx during the 3rd quarter valued at approximately $1,636,000. Barclays PLC grew its stake in MeiraGTx by 107.1% during the 3rd quarter. Barclays PLC now owns 147,827 shares of the company’s stock valued at $618,000 after purchasing an additional 76,437 shares in the last quarter. State Street Corp grew its position in shares of MeiraGTx by 0.9% in the 3rd quarter. State Street Corp now owns 574,727 shares of the company’s stock worth $2,397,000 after acquiring an additional 5,251 shares in the last quarter. Erste Asset Management GmbH acquired a new position in shares of MeiraGTx in the 3rd quarter worth approximately $2,795,000. Finally, Knoll Capital Management LLC acquired a new position in shares of MeiraGTx in the 3rd quarter worth approximately $5,212,000. Institutional investors and hedge funds own 67.48% of the company’s stock.

MeiraGTx Trading Up 0.5 %

Shares of NASDAQ MGTX opened at $6.07 on Friday. The company has a market cap of $474.37 million, a price-to-earnings ratio of -5.02, a price-to-earnings-growth ratio of 0.35 and a beta of 1.26. MeiraGTx Holdings plc has a 12-month low of $3.85 and a 12-month high of $7.37. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 0.86. The stock’s 50 day simple moving average is $6.18 and its 200 day simple moving average is $5.26.

Analyst Ratings Changes

Several research analysts have recently commented on MGTX shares. Royal Bank of Canada lifted their target price on MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Chardan Capital reiterated a “buy” rating and issued a $36.00 target price on shares of MeiraGTx in a research report on Monday, November 18th.

Insider Buying and Selling

In other MeiraGTx news, CFO Richard Giroux sold 24,000 shares of MeiraGTx stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $6.29, for a total transaction of $150,960.00. Following the sale, the chief financial officer now owns 849,947 shares of the company’s stock, valued at $5,346,166.63. The trade was a 2.75 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Alexandria Forbes sold 35,839 shares of MeiraGTx stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $6.47, for a total value of $231,878.33. Following the sale, the chief executive officer now directly owns 1,395,102 shares in the company, valued at $9,026,309.94. The trade was a 2.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 8.40% of the company’s stock.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.